source
- Matchpoint Therapeutics raises $150 million Series B to move oral T-cell modulator MPT-062 toward clinical trialsMatchpoint Therapeutics announced the closing of a $150 million Series B financing round. The round was co-led by Nextech Invest and Norwest, with participation from Sanofi Ventures and several exi…
- Roche partners with China's Defand Therapeutics to discover molecular glue medicinesRoche announced a collaboration with Chinese biotech Defand Therapeutics aimed at discovering new molecular glue medicines for oncology and immune‑mediated diseases. Unlike typical licensing deals…